A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2001
10/11/2001	WO2001074382A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	WO2001074367A1 Pharmaceutical composition based on a non-steroid anti-inflammatory agent
10/11/2001	WO2001074357A1 Hydrophilic molecular disperse solutions of carvedilol
10/11/2001	WO2001074356A1 Concentrated solutions of carvedilol
10/11/2001	WO2001074353A1 A synergistic anti-malarial formulation
10/11/2001	WO2001074337A1 System for transporting active substances in a biological system
10/11/2001	WO2001074336A1 Method for producing a controlled-release preparation
10/11/2001	WO2001074335A1 Pharmaceutical kit comprising midodrine as an active drug substance
10/11/2001	WO2001074333A1 D and l etherlipid stereoisomers and liposomes
10/11/2001	WO2001074330A2 Method for treating dry eye
10/11/2001	WO2001074329A2 Sustained release beadlets containing stavudine
10/11/2001	WO2001074314A2 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
10/11/2001	WO2001074313A2 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins
10/11/2001	WO2001074302A1 Proliposomal encapsulated preparations
10/11/2001	WO2001074299A2 Compositions and methods for inhibition of cancer invasion and angiogenesis
10/11/2001	WO2001074279A1 Topical compositions containing prostaglandin e¿1?
10/11/2001	WO2001074165A1 Chitosan formulation with azelaic acid and other actives for the treatment of acne
10/11/2001	WO2001052833A8 Compositions for delivery of a cortisol antagonist
10/11/2001	WO2001045746A3 Methods and compositions for prolonging elimination half-times of bioactive compounds
10/11/2001	WO2001034677A8 Swelling and deswelling polymer blends
10/11/2001	WO2001028556A3 Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use
10/11/2001	WO2001026621A3 Orally distintegrating composition comprising mirtazapine
10/11/2001	WO2001024763A3 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
10/11/2001	WO2001022947A3 Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
10/11/2001	WO2001021153A3 Pharmaceutical gel containing active substances
10/11/2001	WO2001012579A3 New stilbenes with vascular damaging activity
10/11/2001	WO2001012154A3 Targeted lipid particles
10/11/2001	WO2000042429A3 In vitro model for gastrointestinal inflammation
10/11/2001	US20010029399 Poly (vinyl alcohol) hydrogel
10/11/2001	US20010029357 Enhanced intra vaginal devices
10/11/2001	US20010029287 Thickener for cosmetic, drugs
10/11/2001	US20010029269 Non-steroidal antiinflammatory agent
10/11/2001	US20010029264 In mixture with vitamin e, dimethylisosorbide, citric acid and polyoxyethylene glycol
10/11/2001	US20010029257 Transdermal adminitsering mixture of amine compound in carrier
10/11/2001	US20010029249 Adenovirus comprising a gene coding for glutathione peroxidase
10/11/2001	US20010029046 A deepithelialized skin diffusion cell system comprising, donor and receptor compartments, and a deepithelized skin sample when placed its deepithelialized side faces into donar compartment and dermal side faces into receptor compartment
10/11/2001	US20010029035 For therapy of tumors in which somatostatin receptor is overexpressed
10/11/2001	US20010029020 In vitro determination of metastatic stomach, esophageal, and colorectal cancer from sampling cells outside of the colorectal track for gene transcript or protein
10/11/2001	US20010029019 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
10/11/2001	US20010028899 Composition for supprssing cellular fibrousing and method for preparing an extract from loquat seeds
10/11/2001	US20010028896 Controlled release lipoic acid
10/11/2001	US20010028893 Pressurization
10/11/2001	EP1145001A3 (in vitro) model for gastrointestinal inflammation
10/11/2001	DE10017102A1 Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen A process for producing solid creatine dosage forms and dosage forms obtainable thereby
10/11/2001	DE10015814A1 Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung Medicines to stimulate leukopoiesis, for the treatment of tumors and protozoal diseases and process for its preparation
10/11/2001	DE10015783A1 Transdermales therapeutisches System zur Abgabe von Lerisetron Transdermal therapeutic system for the delivery of lerisetron
10/11/2001	DE10015479A1 Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität Solid oral dosage forms with delayed release and high mechanical stability
10/11/2001	DE10015468A1 Hartkapseln, enthaltend Polymerisate und Vinylestern und Polyethern, deren Verwendung und Herstellung Hard capsules containing polymers and vinyl esters and polyethers, their use and preparation
10/11/2001	CA2405299A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	CA2405293A1 Topical compositions containing prostaglandin e1
10/11/2001	CA2404687A1 Sustained release beadlets containing stavudine
10/11/2001	CA2404369A1 Stable thyroid hormone preparations and method of making same
10/11/2001	CA2404298A1 Amiodarone-containing parenteral solution
10/11/2001	CA2403998A1 Mucin-1 specific binding members and methods of use thereof
10/11/2001	CA2403958A1 Pharmaceutical kit comprising midodrine as an active drug substance
10/11/2001	CA2403885A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001	CA2403661A1 Hydrophilic polymers, pressure sensitive adhesives and coatings
10/11/2001	CA2403242A1 Binding peptides for carcinoembryonic antigen (cea)
10/11/2001	CA2402864A1 D and l etherlipid stereoisomers and liposomes
10/11/2001	CA2401888A1 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
10/10/2001	EP1142987A1 Composition of powdered aureobacidium culture solution, manufacturing method thereof and powder mixture with the composition
10/10/2001	EP1142591A1 Gene carriers
10/10/2001	EP1142589A1 Medicinal preparations
10/10/2001	EP1142588A1 External preparation
10/10/2001	EP1142573A1 Antibacterial medicinal compositions
10/10/2001	EP1142571A1 Method to produce solid creatine dosage forms and dosage forms thus obtained
10/10/2001	EP1142568A1 Pharmaceutical compositions containing cyclosporins
10/10/2001	EP1142566A1 Compositions for ophtalmic use containing cyclosporin, hyaluronic acid and polysorbate
10/10/2001	EP1142565A1 Aqueous medicinal compositions
10/10/2001	EP1141367A1 Synthetic nucleic acid particle
10/10/2001	EP1141365A1 Method for preparing suspension of stable posiplexes
10/10/2001	EP1141364A1 Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane
10/10/2001	EP1141343A1 Non-viral transfection vector
10/10/2001	EP1141334A2 Human glycosylphosphatidylinositol specific phospholipase d variants and uses thereof
10/10/2001	EP1141235A2 (bifidobacterium) in the treatment of inflammatory disease
10/10/2001	EP1141232A1 Preservation of sensitive biologicial materials at ambient temperatures by vitrification
10/10/2001	EP1141124A1 Anionic-cationic polyion complexes comprising zwitterionic monomer component
10/10/2001	EP1141111A1 Gel compositions
10/10/2001	EP1141079A1 Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties
10/10/2001	EP1141023A2 Anti-cd3 immunotoxins and therapeutic uses therefor
10/10/2001	EP1141011A2 Compounds and methods to inhibit or augment an inflammatory response
10/10/2001	EP1141000A1 Superantigens
10/10/2001	EP1140990A1 Penicillins as pharmaceuticals for the downregulation of ifn gamma production
10/10/2001	EP1140966A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
10/10/2001	EP1140965A1 Protonated/acidified nucleic acids and methods of use
10/10/2001	EP1140960A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
10/10/2001	EP1140804A1 Bis-amido polybiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions
10/10/2001	EP1140783A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
10/10/2001	EP1140479A1 Apparatus and method for manufacturing moulded products
10/10/2001	EP1140353A1 Preparation of multiwall polymeric microcapsules from hydrophilic polymers
10/10/2001	EP1140281A1 Thin polymer film drug reservoirs
10/10/2001	EP1140250A1 Method and device for preparing a medical fluid
10/10/2001	EP1140240A1 Injectable hyaluronic acid derivative with pharmaceuticals/cells
10/10/2001	EP1140208A1 Pharmaceutical compositions comprising immortalised endothelial cells
10/10/2001	EP1140202A1 Peptidic product, process and composition
10/10/2001	EP1140201A2 Compounds for intracellular delivery of therapeutic moieties to nerve cells
10/10/2001	EP1140200A1 Anthraquinone anticancer drugs
10/10/2001	EP1140199A1 Hyaluronate lyase used for promoting penetration in topical agents
10/10/2001	EP1140198A1 A composition and method for the enhancement of the efficacy of drugs
10/10/2001	EP1140197A1 Soluble compositions of toremifene

1 ... 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 ... 1712